{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:54:52Z","timestamp":1776848092755,"version":"3.51.2"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ad.2025.104587","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:31:28Z","timestamp":1766593888000},"page":"104587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1751-8959","authenticated-orcid":false,"given":"P.","family":"Balado-Sim\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brufau-Cochs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104587_bib0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ad.2010.07.003","article-title":"Treatment of acne in daily clinical practice: an opinion poll among Spanish dermatologists","volume":"102","author":"Ribera","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.104587_bib0250","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2007.06.045","article-title":"The prevalence of acne in adults 20 years and older","volume":"58","author":"Collier","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ad.2025.104587_bib0260","first-page":"475","article-title":"Acne vulgaris: diagnosis and treatment","volume":"100","author":"Oge\u2019","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ad.2025.104587_bib0265","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/1060028021992053","article-title":"Clascoterone: a novel topical androgen receptor inhibitor for the treatment of acne","volume":"55","author":"Kalabalik-Hoganson","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ad.2025.104587_bib0270","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1080\/14656566.2024.2418986","article-title":"An update on the pharmacological management of acne vulgaris: the state of the art","volume":"25","author":"Valente Duarte de Sousa","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ad.2025.104587_bib0275","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.7573\/dic.2021-8-6","article-title":"Dermatology: how to manage acne vulgaris","volume":"10","author":"Leung","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.ad.2025.104587_bib0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13555-024-01324-8","article-title":"Hormonal therapies for acne: a comprehensive update for dermatologists","volume":"15","author":"Smith","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.104587_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ad.2020.01.020","article-title":"FR-Nuevos f\u00e1rmacos para el manejo del acn\u00e9","volume":"113","author":"Alamon-Reig","year":"2021","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2025.104587_bib0295","unstructured":"US FDA. NDA (213433) approval: Winlevi (clascoterone) cream. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/apple tter\/2020\/213433Orig1s000ltr.pdf Accessed 8.9.20. s. f."},{"key":"10.1016\/j.ad.2025.104587_bib0300","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","volume":"156","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40257-021-00666-9","article-title":"New developments in topical acne therapy","volume":"23","author":"Drake","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0310","article-title":"Individual article: clascoterone cream 1%: mechanism of action, efficacy, and safety of a novel, first-in-class topical antiandrogen therapy for acne","volume":"22","author":"Peterson","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0315","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","volume":"18","author":"Rosette","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","article-title":"Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream","volume":"165","author":"Trifu","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0325","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s40265-020-01417-6","article-title":"Clascoterone: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ad.2025.104587_bib0330","first-page":"570","article-title":"A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne","volume":"18","author":"Mazzetti","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0335","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","article-title":"Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris","volume":"83","author":"Eichenfield","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0340","doi-asserted-by":"crossref","first-page":"810","DOI":"10.36849\/jdd.7592","article-title":"Long-term safety and efficacy of twice-daily topical clascoterone cream 1% in patients greater than or equal to 12 years of age with acne vulgaris","volume":"22","author":"Eichenfield","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0345","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.36849\/JDD.7719","article-title":"Integrated short-term and long-term efficacy of topical clascoterone cream 1% in patients aged 12 years or older with acne vulgaris","volume":"23","author":"Eichenfield","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0350","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14609","article-title":"Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"34","author":"Alkhodaidi","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.104587_bib0355","series-title":"Topical Androgen Receptor Inhibitor for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy. clinicaltrials.gov","author":"Chang","year":"2024"},{"key":"10.1016\/j.ad.2025.104587_bib0360","series-title":"The Efficacy and Safety of Winlevi in Skin of Color Patients With Acne. clinicaltrials.gov","article-title":"Sun Pharmaceutical Industries Limited","year":"2024"},{"key":"10.1016\/j.ad.2025.104587_bib0365","series-title":"Combination Treatment of Winlevi With Duac Gel in Patients With Acne Vulgaris. clinicaltrials.gov","article-title":"Sun Pharmaceutical Industries Limited","year":"2024"},{"key":"10.1016\/j.ad.2025.104587_bib0370","series-title":"The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment. clinicaltrials.gov","article-title":"Sun Pharmaceutical Industries Limited","year":"2024"},{"key":"10.1016\/j.ad.2025.104587_bib0375","doi-asserted-by":"crossref","DOI":"10.36849\/JDD.73361","article-title":"Individual article: real-world cases of clascoterone topical treatment for acne and related disorders","volume":"24","author":"Lynde","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0380","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/CCID.S498879","article-title":"Real-world experience of clascoterone cream 1% in acne management: case series and Canadian experience","volume":"18","author":"Tay","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298155","article-title":"The efficacy of topical clascoterone versus systematic spironolactone for treatment of acne vulgaris: a systematic review and network meta-analysis","volume":"19","author":"Basendwh","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2025.104587_bib0390","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s13555-024-01175-3","article-title":"Comparison of the efficacy of clascoterone, trifarotene, and tazarotene for the treatment of acne: a systematic literature review and meta-analysis","volume":"14","author":"Shergill","year":"2024","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.104587_bib0395","first-page":"20","article-title":"Is there a clinically relevant risk of hyperkalemia with topical clascoterone treatment?","volume":"16","author":"Del Rosso","year":"2023","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0400","doi-asserted-by":"crossref","first-page":"433","DOI":"10.36849\/JDD.7997","article-title":"Hypothalamic\u2013pituitary\u2013adrenal axis response in patients with acne vulgaris treated with clascoterone","volume":"23","author":"Bhatia","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0405","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JD9.0000000000000043","volume":"02","year":"2019","journal-title":"Int J Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104587_bib0410","first-page":"34","article-title":"Acne management guidelines by the Dermatological Society of Singapore","volume":"12","author":"Oon","year":"2019","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0415","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0420","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/1346-8138.14355","article-title":"Japanese dermatological association guidelines: guidelines for the treatment of acne vulgaris 2017","volume":"45","author":"Hayashi","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0425","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bjd.15843","article-title":"Guidelines for the management of acne: recommendations from a French multidisciplinary group","volume":"177","author":"Le Cleach","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0430","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1503\/cmaj.140665","article-title":"Management of acne: Canadian clinical practice guideline","volume":"188","author":"Asai","year":"2016","journal-title":"CMAJ"},{"key":"10.1016\/j.ad.2025.104587_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104587_bib0440","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.12788\/cutis.0844","article-title":"From breakouts to bargains: strategies for patient-centered, cost-effective acne care","volume":"112","author":"Shields","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.104587_bib0445","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-024-01324-8","article-title":"Hormonal therapies for acne: a comprehensive update for dermatologists","author":"Smith","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.104587_bib0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1468-3083.2006.01907.x","article-title":"Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment","volume":"21","author":"Jones-Caballero","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104587_bib0455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-021-00643-2","article-title":"Effects of topical retinoids on acne and post-inflammatory hyperpigmentation in patients with skin of color: a clinical review and implications for practice","volume":"23","author":"Callender","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0460","first-page":"255","article-title":"The role of topical retinoids in prevention and treatment of atrophic acne scarring: understanding the importance of early effective treatment","volume":"18","author":"Tan","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14740338.2020.1757646","article-title":"Adverse events related to topical drug treatments for acne vulgaris","volume":"19","author":"Otlewska","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ad.2025.104587_bib0470","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","article-title":"Androgens in women: hormone-modulating therapies for skin disease","volume":"80","author":"Azarchi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104587_bib0475","series-title":"Clascoterone (Winlevi): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation","year":"2025"},{"key":"10.1016\/j.ad.2025.104587_bib0480","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","volume":"30","author":"Sato","year":"2006","journal-title":"Aesthetic Plast Surg"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:57:16Z","timestamp":1776844636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025008634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0001731025008634"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104587","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104587"}}